This activity is expired and is no longer available for CME credit.


The CME Situation Room: How Will Biosimilars Impact Oncology Care?

Author(s)/Faculty: Hope S. Rugo, MD; Sanjiv S. Agarwala, MD; Edward Li, PharmD, MPH, BCOP
Release Date: 8/13/2018Expiration Date: 8/12/2019
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Biosimilars are highly similar, yet not identical, biological products for an approved reference biologic compound, demonstrating no clinically meaningful differences in quality, safety, or efficacy to the originator product. With the patents expiring for several approved biological therapies utilized in treatment algorithms for patients with cancer, biosimilars of these biological therapies have the potential to reduce health care costs and provide global treatment accessibility. As further biosimilars are approved, it is imperative that all members of the multidisciplinary care team understand the development and evaluation process for these drugs, as well as their interchangeability with the originator product, to foster appropriate incorporation into existing oncology treatment paradigms. In this educational activity, expert faculty review and discuss the development, approval guidelines, and safety profiles of biosimilars, as well as assess the potential impact on oncology-related expenditures. Furthermore, a rapid-fire panel discussion reviews various perspectives concerning the clinical issues around the use of these products.